Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
Ontology highlight
ABSTRACT: SARS-CoV-2 3CL protease is one of the key targets for drug development against COVID-19. Most known SARS-CoV-2 3CL protease inhibitors act by covalently binding to the active site cysteine. Yet, computational screens against this enzyme were mainly focused on non-covalent inhibitor discovery. Here, we developed a deep learning-based stepwise strategy for selective covalent inhibitor screen. We used a deep learning framework that integrated a directed message passing neural network with a feed-forward neural network to construct two different classifiers for either covalent or non-covalent inhibition activity prediction. These two classifiers were trained on the covalent and non-covalent 3CL protease inhibitors dataset, respectively, which achieved high prediction accuracy. We then successi
SUBMITTER: Wang L
PROVIDER: S-EPMC9528019 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA